AAAAAA
Results:
1-16
|
Results: 16
Authors:
MANT T
TROETEL WM
IMBIMBO BP
Citation: T. Mant et al., MAXIMUM TOLERATED DOSE AND PHARMACODYNAMICS OF EPTASTIGMINE IN ELDERLY HEALTHY-VOLUNTEERS, Journal of clinical pharmacology, 38(7), 1998, pp. 610-617
Authors:
GRETLER DD
KITT MM
LAMBING JL
PARK GL
MANT T
Citation: Dd. Gretler et al., PK AND PD PROFILE OF CT50352, A NEW ORAL PLATELET GPIIB-IIIA INHIBITOR, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 13-13
Authors:
RAJMAN I
WISE S
HEMINGWAY J
AMIN D
MANT T
Citation: I. Rajman et al., MODIFIED CARBON-DIOXIDE INHALATION TEST AS A MODEL FOR ANXIETY CHALLENGE, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 53-53
Authors:
JEWELL H
LUCAS R
SCHAEFER HG
MANT T
Citation: H. Jewell et al., LY300164 (LY) INITIAL EXPERIENCE IN HEALTHY-SUBJECTS, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 69-69
Authors:
SCIBERRAS DG
POLVINO WJ
GERTZ BJ
CHENG HY
STEPANAVAGE M
WITTREICH J
OLAH T
EDWARDS M
MANT T
Citation: Dg. Sciberras et al., INITIAL HUMAN-EXPERIENCE WITH MK-462 (RIZATRIPTAN) - A NOVEL 5-HTID AGONIST (VOL 43, PG 49, 1997), British journal of clinical pharmacology, 43(4), 1997, pp. 450-450
Authors:
SCIBERRAS DG
POLVINO WJ
GERTZ BJ
CHENG HY
STEPANAVAGE M
WITTREICH J
OLAH T
EDWARDS M
MANT T
Citation: Dg. Sciberras et al., INITIAL HUMAN-EXPERIENCE WITH MK-462 (RIZATRIPTAN) - A NOVEL 5-HT1D AGONIST, British journal of clinical pharmacology, 43(1), 1997, pp. 49-54
Authors:
LINES C
TRAUB M
RASKIN S
MANT T
REINES S
Citation: C. Lines et al., LACK OF SEDATIVE AND COGNITIVE EFFECTS OF DIPHENHYDRAMINE AND CYCLOBENZAPRINE IN ELDERLY VOLUNTEERS, J PSYCHOPH, 11(4), 1997, pp. 325-329
Authors:
HOUNSLOW N
SHAILER P
HALLAK H
BRON N
MANT T
SIMMONDS H
SEDMAN A
VASSOS A
Citation: N. Hounslow et al., SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF CL-1000, A NEW PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR, IN HEALTHY-VOLUNTEERS, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 98-98
Authors:
SHANAHAN W
GLOVER J
MANT T
AMIN D
LEEDS J
ZUCKERMAN J
LEVIN A
Citation: W. Shanahan et al., PHASE-1 STUDY OF AN ICAM-1 ANTISENSE OLIGONUCLEOTIDE (ISIS-2302), Clinical pharmacology and therapeutics, 59(2), 1996, pp. 80-80
Authors:
BONEU B
NECCIARI J
CARIOU R
SIE P
GABAIG AM
KIEFFER G
DICKINSON J
LAMOND G
MOELKER H
MANT T
MAGNANI H
Citation: B. Boneu et al., PHARMACOKINETICS AND TOLERANCE OF THE NATURAL PENTASACCHARIDE (SR90107 ORG31540) WITH HIGH-AFFINITY TO ANTITHROMBIN-III IN MAN/, Thrombosis and haemostasis, 74(6), 1995, pp. 1468-1473
Authors:
BEER B
IENI JR
WU WH
CLODY D
AMORUSI P
ROSE J
MANT T
GAUDREAULT J
CATO A
STERN W
Citation: B. Beer et al., A PLACEBO-CONTROLLED EVALUATION OF SINGLE, ESCALATING DOSES OF CL-284,846, A NONBENZODIAZEPINE HYPNOTIC, Journal of clinical pharmacology, 34(4), 1994, pp. 335-344
Authors:
IMBIMBO BP
MANT T
EDWARDS M
AMIN D
DALTON N
BOUTIGNON F
LENAERTS V
WUTHRICH P
DEGHENGHI R
Citation: Bp. Imbimbo et al., GROWTH HORMONE-RELEASING ACTIVITY OF HEXARELIN IN HUMANS - A DOSE-RESPONSE STUDY, European Journal of Clinical Pharmacology, 46(5), 1994, pp. 421-425
Authors:
MOYSES C
KOLTERMAN O
NUTTALL A
MANT T
Citation: C. Moyses et al., FIRST ADMINISTRATION TO MAN OF THE HUMAN AMYLIN ANALOG TRIPRO-AMYLIN, Diabetologia, 37, 1994, pp. 10000072-10000072
Authors:
POLVINO W
SCIBERRAS D
GERTZ B
CHENG H
STEPANAVAGE M
WITTREICH J
OLAH T
EDWARDS M
MANT T
Citation: W. Polvino et al., MK-462 - 1ST HUMAN-EXPERIENCE WITH A NOVEL 5-HT1D AGONIST, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 129-129
Authors:
BONEU B
NECCIARI J
MAGNANI H
KIEFFER G
MANT T
MORRISON P
SINGER B
LAMOND G
DICKINSON J
Citation: B. Boneu et al., PHARMACOKINETICS OF THE NATURAL PENTASACCHARIDE (SR 90107A ORG31540) WITH HIGH-AFFINITY FOR ANTITHROMBIN-III FOLLOWING SUBCUTANEOUS ADMINISTRATION IN MAN/, Thrombosis and haemostasis, 69(6), 1993, pp. 655-655
Authors:
MINTON N
SWIFT R
LAWLOR C
MANT T
HENRY J
Citation: N. Minton et al., IPECACUANHA-INDUCED EMESIS - A HUMAN-MODEL FOR TESTING ANTIEMETIC DRUG ACTIVITY, Clinical pharmacology and therapeutics, 54(1), 1993, pp. 53-57
Risultati:
1-16
|